Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) said on Tuesday that it has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC (SWK) on worldwide net revenues from ILUVIEN and YUTIQ.
The one-time payment of USD17.25m eliminates the royalty obligation, effective from 1 January 2025.
The buyout was funded using ANI's cash on hand. This transaction is part of ANI's strategy to strengthen its Retina portfolio and maximise the long-term value of ILUVIEN and YUTIQ.
Nikhil Lalwani, president and CEO of ANI, emphasized that this move enhances the company's financial flexibility and supports its goal of accelerating growth and improving patient outcomes.
Perrigo increases quarterly dividend
AbbVie announces quarterly cash dividend
hVIVO acquires German Clinical Research Units for EUR10m; Targets earnings growth by 2026
OptiBiotix expands into Indian market with Amazon launch
Poxel to receive royalties and sales-based payment from Sumitomo Pharma
ReciBioPharm secures grant to expand RNA manufacturing in LMICs
CVS Health to pays common stock quarterly dividend of USD0.665 per share
TC BioPharm receives shareholders' approval for 25% stock dividend
USANA Health Sciences acquires controlling stake in Hiya Health for USD205m
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
Lilly and EVA Pharma granted regulatory approval for locally manufactured insulin in Egypt
Abbott announces dividend increase and 53 years of growth
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Moberg Pharma's MOB-015 fails to meet primary endpoint in phase 3 study
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine